Humacyte (NASDAQ:HUMA) Insider Shamik Parikh Sells 45,887 Shares

by · The Cerbat Gem

Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) insider Shamik Parikh sold 45,887 shares of the company’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $0.90, for a total transaction of $41,298.30. Following the completion of the transaction, the insider owned 272,713 shares in the company, valued at approximately $245,441.70. This trade represents a 14.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Humacyte Stock Performance

Shares of NASDAQ HUMA opened at $0.92 on Thursday. The company has a market cap of $203.64 million, a PE ratio of -1.61 and a beta of 2.31. Humacyte, Inc. has a 12 month low of $0.55 and a 12 month high of $2.93. The company has a debt-to-equity ratio of 5.46, a current ratio of 3.93 and a quick ratio of 3.32. The company has a 50-day simple moving average of $0.84 and a 200-day simple moving average of $1.04.

Humacyte (NASDAQ:HUMA – Get Free Report) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. Humacyte had a negative net margin of 4,836.06% and a negative return on equity of 2,914.18%. The business had revenue of $0.50 million for the quarter, compared to the consensus estimate of $1.46 million. On average, equities analysts anticipate that Humacyte, Inc. will post -0.32 earnings per share for the current year.

Hedge Funds Weigh In On Humacyte

Institutional investors have recently made changes to their positions in the business. Concurrent Investment Advisors LLC raised its stake in shares of Humacyte by 16.6% in the 3rd quarter. Concurrent Investment Advisors LLC now owns 59,615 shares of the company’s stock valued at $104,000 after purchasing an additional 8,500 shares in the last quarter. SG Americas Securities LLC boosted its position in Humacyte by 50.3% during the 4th quarter. SG Americas Securities LLC now owns 34,075 shares of the company’s stock valued at $33,000 after purchasing an additional 11,411 shares during the period. Independent Advisor Alliance grew its position in shares of Humacyte by 49.4% during the third quarter. Independent Advisor Alliance now owns 36,240 shares of the company’s stock worth $63,000 after acquiring an additional 11,991 shares during the last quarter. Prudential Financial Inc. bought a new stake in Humacyte in the 2nd quarter valued at about $28,000. Finally, Price T Rowe Associates Inc. MD boosted its stake in Humacyte by 21.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 76,017 shares of the company’s stock valued at $73,000 after purchasing an additional 13,175 shares during the period. 44.71% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Wall Street Zen upgraded Humacyte from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. BTIG Research dropped their target price on Humacyte from $3.00 to $2.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. Benchmark decreased their price target on Humacyte from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, January 21st. D. Boral Capital restated a “buy” rating and issued a $25.00 price target on shares of Humacyte in a report on Tuesday, April 28th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Humacyte in a research note on Friday, April 10th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Humacyte presently has an average rating of “Moderate Buy” and a consensus price target of $7.57.

Read Our Latest Research Report on HUMA

About Humacyte

(Get Free Report)

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.

Recommended Stories